Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. (Q51726149)

10 April 2018

title

Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. (English)

1 reference

10 April 2018

main subject

type 2 diabetes

0 references

author name string

Jazlina Liza Jamaluddin

series ordinal

1 reference

10 April 2018

Hasniza Zaman Huri

series ordinal

1 reference

10 April 2018

Shireene Ratna Vethakkan

series ordinal

1 reference

10 April 2018

publication date

1 June 2016

1 reference

10 April 2018

published in

Pharmacogenomics

1 reference

10 April 2018

volume

1 reference

10 April 2018

issue

1 reference

10 April 2018

page(s)

867-881

1 reference

10 April 2018

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Genetic variants affecting incretin sensitivity and incretin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

DPP-4 inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Roles of KATP channels as metabolic sensors in acute metabolic changes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Sample size requirements for association studies of gene-gene interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Predictive validity of a medication adherence measure in an outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Good or evil: CD26 and HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

On the probability of Neanderthal ancestry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Signatures of natural selection in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The use of racial, ethnic, and ancestral categories in human genetics research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

A follow-up case-control association study of tractable (druggable) genes in recurrent major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Detailed investigation of the role of common and low-frequency WFS1 variants in type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Genetic Association Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

DPP4 Gene DNA Methylation in the Omentum is Associated With Its Gene Expression and Plasma Lipid Profile in Severe Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with Type 2 diabetes and hypertension in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0010

21 January 2018

Identifiers

DOI

10.2217/PGS-2016-0010

1 reference

10 April 2018

1 reference

10 April 2018